In the field of B-cell malignancies, CD19 CAR-T cell therapy has achieved remarkable success and sparked the enthusiasm of researchers to explore more targets for the treatment of other hematological malignancies and solid tumors. This evidence concerns the gene CD19 and hematologic disorder.